吡非尼酮在肿瘤治疗中的研究进展OA

Pirfenidone,an FDA-approved drug for idiopathic pulmonary fibrosis,has demonstrated potential in cancer therapy due to its anti-fibrotic,antioxidant,and anti-inflammatory properties.Research has shown that pirfenidone directly inhibits tumor cell proliferation and metastasis through multiple mechanisms,including the suppression of key signaling path-ways(e.g.,TGF-β/SMAD),cell cycle regulation,apoptosis induction,and the inhibition of epithelial-mesenchymal tran-sition.In addition,pirfenidone enhances anti-tumor immune responses indirectly by remodeling the tumor microenvironment,primarily by inhibiting extracellular matrix deposition;modulating cance-associated fibroblast function;and promoting im-mune cell infiltration and polarization.Furthermore,combining pirfenidone with chemotherapy,targeted therapy,or immune checkpoint inhibitors exhibits synergistic effects,presenting a promising strategy to overcome tumor drug resistance and im-mune suppression.Therefore,further in-depth research and clinical trials are expected to clarify the broad application value of pirfenidone in cancer treatment,providing more therapeutic options for cancer patients.